| Literature DB >> 33664418 |
Yusuke Azami1, Naohiro Tsuyama2, Yu Abe2, Misaki Sugai-Takahashi2, Ken-Ichi Kudo2, Akinobu Ota3, Karnan Sivasundaram3, Moe Muramatsu4, Tomonari Shigemura5, Megumi Sasatani6, Yuko Hashimoto4, Shigehira Saji1, Kenji Kamiya6, Ichiro Hanamura3, Takayuki Ikezoe7, Masafumi Onodera8, Akira Sakai9.
Abstract
Multiple myeloma (MM) cells are derived from mature B cells based on immunoglobulin heavy chain (IgH) gene analysis. The onset of MM is often caused by a reciprocal chromosomal translocation (cTr) between chr 14 with IgH and chr 11 with CCND1. We propose that mature B cells gain potential to transform by reprograming, and then chromosomal aberrations cause the development of abnormal B cells as a myeloma-initiating cell during B cell redifferentiation. To study myeloma-initiating cells, we have already established normal B cell-derived induced pluripotent stem cells (BiPSCs). Here we established two BiPSCs with reciprocal cTr t(11;14) using the CRISPR/Cas9 system; the cleavage site were located in the IgH Eμ region of either the VDJ rearranged allele or non-rearranged allele of IgH and the 5'-upsteam region of the CCND1 (two types of BiPSC13 with t(11;14) and MIB2-6 with t(11;14)). Furthermore, p53 was deleted using the CRISPR/Cas9 system in BiPSC13 with t(11;14). These BiPSCs differentiated into hematopoietic progenitor cells (HPCs). However, unlike cord blood, those HPCs did not differentiated into B lymphocytes by co-culture with BM stromal cell. Therefore, further ingenuity is required to differentiate those BiPSCs-derived HPCs into B lymphocytes.Entities:
Mesh:
Substances:
Year: 2021 PMID: 33664418 PMCID: PMC7933289 DOI: 10.1038/s41598-021-84628-5
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379